CinPhloro Pharma, A CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D CinPhloro Pharma Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D.
